Centogene is a worldwide leader in the field of genetic diagnostic testing for rare hereditary diseases, with a broad test portfolio covering over 2800 genes, biochemical tests, biomarker and clinical whole exome sequencing and whole genome sequencing.

The Almac Group is an established contract development and manufacturing organisation that provides an extensive range of integrated services globally to companies within the pharmaceutical and biotech sectors. They work across all therapeutic areas for a wide range of organisations.

Spherix have extensive experience in biopharmaceutical brand management and strategic marketing, coupled with a passion for the specialty markets that they cover. Spherix regularly consults with an advisory board who oversee their research activities.

PTC Therapeutics are focused on discovering and developing novel oral treatments for patients with serious and life-limiting disorders. By targeting the processes that modulate RNA biology and affect protein production, they bring an innovative approach to drug discovery.

Cydan is the first orphan drug accelerator dedicated to advancing therapies that improve the lives of patients with rare genetic diseases. They are doing this because there are more than 7,000 rare diseases, with approximately 400 approved treatments. That’s not good enough.